Literature DB >> 18582800

C3d and C4d deposition early after lung transplantation.

Glen P Westall1, Greg I Snell, Catriona McLean, Tom Kotsimbos, Trevor Williams, Cynthia Magro.   

Abstract

BACKGROUND: Complement staining as a predictor of antibody-mediated rejection (AMR) after lung transplantation continues to be debated.
METHODS: In a cohort of 33 lung transplant recipients (LTRs) we assessed early post-transplant (<or=3 months) graft deposition of the complement factors C3d and C4d and correlated staining with clinical outcome. A retrospective analysis of allograft C3d and C4d deposition was performed by an experienced histopathologist blinded to clinical outcomes. Biopsies were graded 0 to 3 based on extent of septal capillary complement staining.
RESULTS: Significant C3d and C4d staining (i.e., Grade >or=2 on more than one occasion) was observed in 20 and 11 LTRs, respectively. Complement staining was increased in LTRs with severe primary graft dysfunction or airway infection, but was not associated with acute cellular or chronic rejection, or with morphologic features of AMR. In a sub-group analysis we identified 9 LTRs who developed early bronchiolitis obliterans syndrome (BOS) in the absence of acute cellular rejection or cytomegalovirus reactivation, but they had significant lung allograft C3d/C4d deposition along with corroborative light-microscopic features suggestive of AMR.
CONCLUSIONS: Complement activation, as judged by lung allograft deposition of C3d/C4d, is common early post-lung transplant and may be triggered by primary graft dysfunction and/or airway infection, and may play a role in the development of early BOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582800     DOI: 10.1016/j.healun.2008.03.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  25 in total

Review 1.  Acute rejection.

Authors:  Mark Benzimra; Greg L Calligaro; Allan R Glanville
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Antibody-mediated Rejection in Lung Transplantation.

Authors:  Hrishikesh S Kulkarni; Bradford C Bemiss; Ramsey R Hachem
Journal:  Curr Transplant Rep       Date:  2015-09-30

Review 3.  Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction.

Authors:  David S Wilkes
Journal:  Semin Immunol       Date:  2011-09-16       Impact factor: 11.130

4.  Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection.

Authors:  Ankit Bharat; Deepti Saini; Nancy Steward; Ramsey Hachem; Elbert P Trulock; G Alexander Patterson; Bryan F Meyers; Thalachallour Mohanakumar
Journal:  Ann Thorac Surg       Date:  2010-10       Impact factor: 4.330

Review 5.  Pros and cons for C4d as a biomarker.

Authors:  Danielle Cohen; Robert B Colvin; Mohamed R Daha; Cinthia B Drachenberg; Mark Haas; Volker Nickeleit; Jane E Salmon; Banu Sis; Ming-Hui Zhao; Jan A Bruijn; Ingeborg M Bajema
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

6.  Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients.

Authors:  Angali Golocheikine; Dilip S Nath; Haseeb Ilias Basha; Deepti Saini; Donna Phelan; Aviva Aloush; Elbert P Trulock; Ramsey R Hachem; G Alexander Patterson; Joseph M Ahearn; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2010-04       Impact factor: 10.247

7.  Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.

Authors:  Laurie D Snyder; Ziwei Wang; Dong-Feng Chen; Nancy L Reinsmoen; C Ashley Finlen-Copeland; W Austin Davis; David W Zaas; Scott M Palmer
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

8.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

9.  Pathologic findings in lung allografts with anti-HLA antibodies.

Authors:  Matthew M DeNicola; Sam S Weigt; John A Belperio; Elaine F Reed; David J Ross; W Dean Wallace
Journal:  J Heart Lung Transplant       Date:  2013-01-10       Impact factor: 10.247

Review 10.  Acute rejection and humoral sensitization in lung transplant recipients.

Authors:  Tereza Martinu; Dong-Feng Chen; Scott M Palmer
Journal:  Proc Am Thorac Soc       Date:  2009-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.